Immunobiology of human imunodeficiency virus infection

Indian Journal of Medical Microbiology

Volumn 25, Issue 4, 2007, Pages 311-322

  Tripathi, P ^a   Agrawal, S ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Acquired immune deficiency syndrome; Human immunodeficiency virus; Macrophages; NK cells; T cell

Indexed keywords

ENVELOPE PROTEIN; GAG PROTEIN; MESSENGER RNA; NEF PROTEIN; REV PROTEIN; TRANSACTIVATOR PROTEIN; VIF PROTEIN; VIRUS DNA; VIRUS RNA; VPR PROTEIN; VPU PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIGEN RECOGNITION; CD4+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ENVELOPE GENE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOBIOLOGY; MACROPHAGE; MOLECULAR BIOLOGY; NATURAL KILLER CELL; NONHUMAN; REVIEW; STRUCTURAL GENE; T LYMPHOCYTE; VIRUS TRANSMISSION;

EID: 37549000962     PISSN: 02550857     EISSN: 02550857     Source Type: Journal    
DOI: 10.4103/0255-0857.37332     Document Type: Review

References (127)

1. Surendran A. AIDS infections, deaths hit record high in 2003. Nat Med 2004;10:4.
2. Schwartz O, Marechal V, Le Gall S, Lemonnier F, Heard JM. Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat Med 1996;2:338-42.
3. Vaishnav YN, Wong-Staal F. The biochemistry of AIDS. Annu Rev Biochem 1991;60:577-630.
4. Greene WC. The molecular biology of human immunodeficiency virus type 1 infection. N Engl J Med 1991;324:308-17.
5. Le SY, Malim MH, Cullen BR, Maizel JV. A highly conserved RNA folding region coincident with the Rev response element of primate immunodeficiency viruses. Nucleic Acids Res 1990;18:1613-23.
6. Malim MH, Hauber J, Le SY, Maizel JV, Cullen BR. The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. Nature 1989;338:254-7.
7. Herrmann CH, Rice AP. Lentivirus Tat proteins specifically associate with a cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase II: Candidate for a Tat cofactor. J Virol 1995;69:1612-20.
8. Cullen BR. HIV-1 auxiliary proteins: Making connections in a dying cell. Cell 1998;93:685-92.
9. Borrow P, Lewicki H, Wei X, Horwitz MS, Peffer N, Meyers H, et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 1997;3:205-11.
10. Sackett K, Wexler-Cohen Y, Shai Y. Characterization of the HIV N-terminal fusion peptide-containing region in context of key gp41 fusion conformations. J Biol Chem 2006;281:21755-62.
11. Delwart EL, Mosialos G, Gilmore T. Retroviral envelope glycoproteins contain a "leucine zipper"-like repeat. AIDS Res Hum Retroviruses 1990;6:703-6.
12. Zanetti G, Briggs JA, Grünewald K, Sattentau QJ, Fuller SD. Cryo-electron tomographic structure of an immunodeficiency virus envelope complex in situ. PLoS Pathog 2006;2:e83.
13. Doms RW, Trono D. The plasma membrane as a combat zone in the HIV battlefield. Genes Dev 2000;14:2677-88.
14. Weiss CD, Levy JA, White JM. Oligomeric organization of gp120 on infectious human immunodeficiency virus type 1 particles. J Virol 1990;64:5674-7.
15. Carr CM, Kim PS. A spring-loaded mechanism for the conformational change of influenza hemagglutinin. Cell 1993;73:823-32.
16. Chen CH, Matthews TJ, McDanal CB, Bolognesi DP, Greenberg ML. A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: Implication for viral fusion. J Virol 1995;69:3771-7.
17. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1 alpha and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995;270:1811-5.
18. Agrawal L, Vanhorn-Ali Z, Alkhatib G. Multiple determinants are involved in HIV coreceptor use as demonstrated by CCR4/CCL22 interaction in peripheral blood mononuclear cells (PBMCs). J Leukoc Biol 2002;72:1063-74.
19. James W, Weiss RA, Simon JH. The receptor for HIV: Dissection of CD4 and studies on putative accessory factors. Curr Top Microbiol Immunol 1996;205:137-58.
20. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996;272:872-7.
21. Oberlin E, Amara A, Bachelerie F, Bessia C, Virelizier JL, Arenzana-Seisdedos F, et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cellline-adapted HIV-1. Nature 1996;382:833-5.
22. Bleul CC, Farzan M, Choe H, Parolin C, Clark-Lewis I, Sodroski J, et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 1996;382:829-33.
23. + cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996;381:667-73.
24. Cartier C, Sivard P, Tranchat C, Decimo D, Desgranges C, Boyer V. Identification of three major phosphorylation sites within HIV-1 capsid. Role of phosphorylation during the early steps of infection. J Biol Chem 1999;274:19434-40.
25. Franke EK, Yuan HE, Luban J. Specific incorporation of cyclophilin A into HIV-1 virions. Nature 1994;372:359-62.
26. Schaeffer E, Geleziunas R, Greene WC. Human immunodeficiency virus type 1 Nef functions at the level of virus entry by enhancing cytoplasmic delivery of virions. J Virol 2001;75:2993-3000.
27. Ohagen A, Gabuzda D. Role of Vif in stability of the human immunodeficiency virus type 1 core. J Virol 2000;74:11055-66.
28. Lu X, Yu H, Liu SH, Brodsky FM, Peterlin BM. Interactions between HIV1 Nef and vacuolar ATPase facilitate the internalization of CD4. Immunity 1998;8:647-56.
29. Takeda M, Khamdang S, Narikawa S, Kimura H, Kobayashi Y, Yamamoto T, et al. Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther 2002;300:918-24.
30. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996;381:661-6.
31. Karageorgos L, Li P, Burrell C. Characterization of HIV replication complexes early after cell-to-cell infection. AIDS Res Hum Retroviruses 1993;9:817-23.
32. + cell depletion and progression to AIDS. Ann Intern Med 1993;118:681-8.
33. Richman DD, Bozzette SA. The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 1994;169:968-74.
34. Marechal V, Prevost MC, Petit C, Perret E, Heard JM, Schwartz O. Human immunodeficiency virus type 1 entry into macrophages mediated by macropinocytosis. J Virol 2001;75:11166-77.
35. McDonald D, Vodicka MA, Lucero G, Svitkina TM, Borisy GG, Emerman M, et al. Visualization of the intracellular behavior of HIV in living cells. J Cell Biol 2002;159:441-52.
36. Bukrinskaya A, Brichacek B, Mann A, Stevenson M. Establishment of a functional human immunodeficiency virus type 1 (HIV- reverse transcription complex involves the cytoskeleton. J Exp Med 1998;188:2113-25.
37. Wu X anderson JL, Campbell EM, Joseph AM, Hope TJ. Proteasome inhibitors uncouple rhesus TRIM5alpha restriction of HIV-1 reverse transcription and infection. Proc Natl Acad Sci USA 2006;103:7465-70.
38. de Soultrait VR, Caumont A, Durrens P, Calmels C, Parissi V, Recordon P, et al. HIV-1 integrase interacts with yeast microtubule-associated proteins. Biochim Biophys Acta 2002;1575:40-8.
39. Campbell EM, Nunez R, Hope TJ. Disruption of the actin cytoskeleton can complement the ability of Nef to enhance human immunodeficiency virus type 1 infectivity. J Virol 2004;78:5745-55.
40. Saib A, Puvion-Dutilleul F, Schmid M, Peries J, de The H. Nuclear targeting of incoming human foamy virus Gag proteins involves a centriolar step. J Virol 1997;71:1155-61.
41. Petit C, Giron ML, Tobaly-Tapiero J, Bittoun P, Real E, Jacob Y, et al. Targeting of incoming retroviral Gag to the centrosome involves a direct interaction with the dynein light chain 8. J Cell Sci 2003;116:3433-42.
42. Miller MD, Farnet CM, Bushman FD. Human immunodeficiency virus type 1 preintegration complexes: Studies of organization and composition. J Virol 1997;71:5382-90.
43. Pante N, Kann M. Nuclear pore complex is able to transport macromolecules with diameters of about 39 nm. Mol Biol Cell 2002;13:425-34.
44. Sherman MP, de Noronha CM, Heusch MI, Greene S, Greene WC. Nucleocytoplasmic shuttling by human immunodeficiency virus type 1 Vpr. J Virol 2001;75:1522-32.
45. Cullen BR. Journey to the center of the cell. Cell 2001;105:697-700.
46. + T cells. J Exp Med 2001;194:1407-19.
47. Vodicka MA, Koepp DM, Silver PA, Emerman M. HIV-1 Vpr interacts with the nuclear transport pathway to promote macrophage infection. Genes Dev 1998;12:175-85.
48. Sherman MP, Greene WC. Slipping through the door: HIV entry into the nucleus. Microbes Infect 2002;4:67-73.
49. Haffar OK, Popov S, Dubrovsky L, Agostini I, Tang H, Pushkarsky T, et al. Two nuclear localization signals in the HIV-1 matrix protein regulate nuclear import of the HIV-1 preintegration complex. J Mol Biol 2000;299:359-68.
50. Miller MD, Farnet CM, Bushman FD. Human immunodeficiency virus type 1 preintegration complexes: Studies of organization and composition. J Virol 1997;71:5382-90.
51. Chen H, Engelman A. The barrier-to-autointegration protein is a host factor for HIV type 1 integration. Proc Natl Acad Sci USA 1998;95:15270-4.
52. Ciuffi A, Llano M, Poeschla E, Hoffmann C, Leipzig J, Shinn P, et al. A role for LEDGF/p75 in targeting HIV DNA integration. Nat Med 2005;11:1287-9.
53. Faure A, Calmels C, Desjobert C, Castroviejo M, Caumont-Sarcos A, Tarrago-Litvak L, et al. HIV-1 integrase cross-linked oligomers are active in vitro. Nucleic Acids Res 2005;33:977-86.
54. Li M, Mizuuchi M, Burke TR Jr, Craigie R. Retroviral DNA integration: Reaction pathway and critical intermediates. EMBO J 2006;25:1295- 304.
55. Doms RW, Trono D. The plasma membrane as a combat zone in the HIV battlefield. Genes Dev 2000;14:2677-88.
56. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR. Change in coreceptor use coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 1997;185:621-8.
57. Zhang Y, Lou B, Lal RB, Gettie A, Marx PA, Moore JP. Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells. J Virol 2000;74:6893-910.
58. McDougal JS, Mawle A, Cort SP, Nicholson JK, Cross GD, Scheppler-Campbell JA, et al. Cellular tropism of the human retrovirus HTLV-III/LAV, I: Role of T cell activation and expression of the T4 antigen. J Immunol 1985;135:3151-62.
59. + T cells. Nature 2002;417:95-8.
60. + T cells but a high proportion of replication-competent provirus copies in asymptomatic human immunodeficiency virus type 1 infection. J Virol 1991;65:2019-23.
61. Finkel TH, Banda NK. Indirect mechanisms of HIV pathogenesis: How does HIV kill T cells? Curr Opin Immunol 1994;6:605-15.
62. Ameisen JC, Capron A. Cell dysfunction and depletion in AIDS: The programmed cell death hypothesis. Immunol Today 1991;12:102-5.
63. Greenberg M, DeTulleo L, Rapoport I, Skowronski J, Kirchhausen T. A dileucine motif in HIV-1 Nef is essential for sorting into clathrin-coated pits and for downregulation of CD4. Curr Biol 1998;8:1239-42.
64. Greenberg ME, Bronson S, Lock M, Neumann M, Pavlakis GN, Skowronski J. Co-localization of HIV-1 Nef with the AP-2 adaptor protein complex correlates with Nef-induced CD4 down-regulation. EMBO J 1997;16:6964-76.
65. + T cells. Nature 2005;434:1148-52.
66. Boirivant M, Viora M, Giordani L, Luzzati AL, Pronio AM, Montesani C, et al. HIV-1 gp120 accelerates Fas-mediated activation-induced human lamina propria T cell apoptosis. J Clin Immunol 1998;18:39-47.
67. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994;68:4650-5.
68. Phillips AN. Reduction of HIV concentration during acute infection: Independence from a specific immune response. Science 1996;271:497-9.
69. Schwartz EJ, Neumann AU, Teixeira AV, Bruggeman LA, Rappaport J, Perelson AS, et al. Effect of target cell availability on HIV-1 production in vitro. AIDS 2002;16:341-5.
70. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci USA 2003;100:4144-9.
71. Borrow P, Lewicki H, Wei X, Horwitz MS, Peffer N, Meyers H, et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 1997;3:205-11.
72. Gartner S, Markovits P, Markovitz DM, Kaplan MH, Gallo RC, Popovic M. The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 1986;233:215-9.
73. Finkel TH, Tudor-Williams G, Banda NK, Cotton MF, Curiel T, Monks C, et al. Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV-and SIV-infected lymph nodes. Nat Med 1995;1:129-34.
74. Banda NK, Bernier J, Kurahara DK, Kurrle R, Haigwood N, Sekaly RP, et al. Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis. J Exp Med 1992;176:1099-106.
75. Swingler S, Mann A, Jacque J, Brichacek B, Sasseville VG, Williams K, et al. HIV-1 Nef mediates lymphocyte chemotaxis and activation by infected macrophages. Nat Med 1999;5:997-103.
76. Badley AD, McElhinny JA, Leibson PJ, Lynch DH, Alderson MR, Paya CV. Upregulation of Fas ligand expression by human immunodeficiency virus in human macrophages mediates apoptosis of uninfected T lymphocytes. J Virol 1996;70:199-206.
77. Zheng L, Fisher G, Miller RE, Peschon J, Lynch DH, Lenardo MJ. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 1995;377:348-51.
78. Herbein G, Mahlknecht U, Batliwalla F, Gregersen P, Pappas T, Butler J, et al. Apoptosis of CD8+ T cells is mediated by macrophages through interaction of HIV gp120 with chemokine receptor CXCR4. Nature 1998;395:189-94.
79. + T lymphocytes is mediated by macrophages: Role for Nef and immune activation in viral persistence. J Immunol 2000;165:6437-46.
80. Trujillo JR, Rogers R, Molina RM, Dangond F, McLane MF, Essex M, et al. Noninfectious entry of HIV-1 into peripheral and brain macrophages mediated by the mannose receptor. Proc Natl Acad Sci USA 2007;104:5097-102.
81. Trujillo JR, Rogers RA, Brain JD. Shared antigenic epitopes on the V3 loop of HIV-1 gp120 and proteins on activated human T cells. Virology 1998;246:53-62.
82. Mavilio D, Benjamin J, Daucher M, Lombardo G, Kottilil S, Planta MA, et al. Natural killer cells in HIV-1 infection: Dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates. Proc Natl Acad Sci USA 2003;100:15011-6.
83. Cohen GB, Gandhi RT, Davis DM, Mandelboim O, Chen BK, Strominger JL, et al. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 1999;10:661-71.
84. Ward JP, Bonaparte MI, Barker E. HLA-C and HLA-E reduce antibody-dependent natural killer cell-mediated cytotoxicity of HIV-infected primary T cell blasts. AIDS 2004;18:1769-79.
85. Kottilil S, Chun TW, Moir S, Liu S, McLaughlin M, Hallahan CW, et al. Innate immunity in human immunodeficiency virus infection: Effect of viremia on natural killer cell function. J Infect Dis 2003;187:1038-45.
86. Oliva A, Kinter AL, Vaccarezza M, Rubbert A, Catanzaro A, Moir S, et al. Natural killer cells from human immunodeficiency virus (HIV)-infected individuals are an important source of CC-chemokines and suppress HIV-1 entry and replication in vitro. J Clin Invest 1998;102:223-31.
87. Scott-Algara D, Truong LX, Versmisse P, David A, Luong TT, Nguyen NV, et al. Cutting edge: Increased NK cell activity in HIV-1-exposed but uninfected Vietnamese intravascular drug users. J Immunol 2003;171:5663-7.
88. Valentin A, Rosati M, Patenaude DJ, Hatzakis A, Kostrikis LG, Lazanas M, et al. Persistent HIV-1 infection of natural killer cells in patients receiving highly active antiretroviral therapy. Proc Natl Acad Sci USA 2002;99:7015-20.
89. Fogli M, Costa P, Murdaca G, Setti M, Mingari MC, Moretta L, et al. Significant NK cell activation associated with decreased cytolytic function in peripheral blood of HIV-1-infected patients. Eur J Immunol 2004;34:2313-21.
90. Mavilio D, Lombardo G, Benjamin J, Kim D, Follman D, Marcenaro E, et al. Characterization of CD56-/CD16+ natural killer (NK) cells: A highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc Natl Acad Sci USA 2005;102:2886-91.
91. Rodriguez AR, Arulanandam BP, Hodara VL, McClure HM, Cobb EK, Salas MT, et al. Influence of interleukin-15 on CD8+ natural killer cells in human immunodeficiency virus type 1-infected chimpanzees. J Gen Virol 2007;88:641-51.
92. Kottilil S, Shin K, Jackson JO, Reitano KN, O'Shea MA, Yang J, et al. Innate immune dysfunction in HIV infection: Effect of HIV envelope-NK cell interactions. J Immunol 2006;176:1107-14.
93. Blagoveshchenskaya AD, Thomas L, Feliciangeli SF, Hung CH, Thomas G. HIV-1 Nef downregulates MHC-I by a PACS-1- and PI3K-regulated ARF6 endocytic pathway. Cell 2002;111:853-66.
94. Piguet V, Gu F, Foti M, Demaurex N, Gruenberg J, Carpentier JL, et al. Nef-induced CD4 degradation: A diacidic-based motif in Nef functions as a lysosomal targeting signal through the binding of beta-COP in endosomes. Cell 1999;97:63-73.
95. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-52.
96. Caux C, Vanbervliet B, Massacrier C, Dubois B, de Saint Vis B, Fayette J, et al. In vitro regulation of development and function of dendritic cells. Hematol Cell Ther 1996;38:463.
97. Rubbert A, Combadiere C, Ostrowski M, Arthos J, Dybul M, Machado E, et al. Dendritic cells express multiple chemokine receptors used as coreceptors for HIV entry. J Immunol 1998;160:3933-41.
98. Turville SG, Arthos J, Donald KM, Lynch G, Naif H, Clark G, et al. HIV gp120 receptors on human dendritic cells. Blood 2001;98:2482- 8.
99. + T cells clonal expansion. Clin Exp Immunol 1992;88:226-36.
100. Geijtenbeek TB, Kwon DS, Torensma R, van Vliet SJ, van Duijnhoven GC, Middel J, et al. DC-SIGN, a dendritic cell specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 2000;100:587-97.
101. Hu Q, Frank I, Williams V, Watts P, Moore JP, Pope M, et al. Blockade of attachment and fusion receptors inhibits HIV-1 infection of human cervical tissue. J Exp Med 2004;199:1065-75.
102. Heath SL, Tew JG, Tew JG, Szakal AK, Burton GF. Follicular dendritic cells and human immunodeficiency virus infectivity. Nature 1995;377:740-4.
103. Burton GF, Keele BF, Estes JD, Thacker TC, Gartner S. Follicular dendritic cell contributions to HIV pathogenesis. Semin Immunol 2002;14:275-84.
104. Smith BA, Gartner S, Liu Y, Perelson AS, Stilianakis NI, Keele BF, et al. Persistence of infectious HIV on follicular dendritic cells. J Immunol 2001;166:690-6.
105. + T cells in response to antigen depends on close contact through adhesion molecules. Virology 1997;239:259-68.
106. Wiley RD, Gummuluru S. Immature dendritic cell-derived exosomes can mediate HIV-1 trans infection. Proc Natl Acad Sci USA 2006;103:738-43.
107. Berke G. The CTL's kiss of death. Cell 1995;81:9-12.
108. Tschopp J, Hofmann K. Cytotoxic T cells: More weapons for new targets? Trends Microbiol 1996;4:91-4.
109. Cocchi F, DeVico AL, Garzino-Demo A, Cara A, Gallo RC, Lusso P. The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. Nat Med 1996;2:1244-7.
110. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1 alpha and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995;270:1811-5.
111. Rowland-Jones SL, Nixon DF, Aldhous MC, Gotch F, Ariyoshi K, Hallam N, et al. HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant. Lancet 1993;341:860-1.
112. Looney DJ. Immune responses to human immunodeficiency virus type 1 in exposed but uninfected individuals: Protection or chance? J Clin Invest 1994;93:920.
113. Ogg GS, Jin X, Bonhoeffer S, Dunbar PR, Nowak MA, Monard S, et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 1998;279:2103-6.
114. Yu XG, Addo MM, Rosenberg ES, Rodriguez WR, Lee PK, Fitzpatrick CA, et al. Consistent patterns in the development and immunodominance of human immunodeficiency virus type 1 (HIV - specific CD8+ T-cell responses following acute HIV-1 infection. J Virol 2002;76:8690-701.
115. Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell JI, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996;274:94-6.
116. Kuroda MJ, Schmitz JE, Charini WA, Nickerson CE, Lord CI, Forman MA, et al. Comparative analysis of cytotoxic T lymphocytes in lymph nodes and peripheral blood of simian immunodeficiency virus-infected rhesus monkeys. J Virol 1999;73:1573-9.
117. Zhang Z, Zhao QX, Fu JL, Yao JX, He Y, Jin L, et al. Characteristics of HIV-1-specific CD8 T-cell responses and their role in loss of viremia in children chronically infected with HIV-1 undergoing highly active antiretroviral therapy. Chin Med J (Engl) 2006;119:1949-57.
118. Goulder PJ, Altfeld MA, Rosenberg ES, Nguyen T, Tang Y, Eldridge RL, et al. Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection. J Exp Med 2001;193:181- 94.
119. Coffin JM. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis and therapy. Science 1995;267:483- 9.
120. McAdam S, Klenerman P, Tussey L, Rowland-Jones S, Lalloo D, Phillips R, et al. Immunogenic HIV variant peptides that bind to HLA-B8 can fail to stimulate cytotoxic T lymphocyte responses. J Immunol 1995;155:2729-36.
121. Moore CB, John M, James IR, Christiansen FT, Witt CS, Mallal SA. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 2002;296:1439-43.
122. Goulder PJ, Phillips RE, Colbert RA, McAdam S, Ogg G, Nowak MA, et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med 1997;3:212-7.
123. Carrington M, Nelson GW, Martin MP, Kissner T, Vlahov D, Goedert JJ, et al. HLA and HIV-1: Heterozygote advantage and B*35-Cw*04 disadvantage. Science 1999;283:1748-52.
124. Friedrich TC, Dodds EJ, Yant LJ, Vojnov L, Rudersdorf R, Cullen C, et al. Reversion of CTL escape-variant immunodeficiency viruses in vivo. Nat Med 2004;10:275-81.
125. Leslie AJ, Pfafferott KJ, Chetty P, Draenert R, Addo MM, Feeney M, et al. HIV evolution: CTL escape mutation and reversion after transmission. Nat Med 2004;10:282-9.
126. Migueles SA, Laborico AC, Imamichi H, Shupert WL, Royce C, McLaughlin M, et al. The differential ability of HLA B*5701+ long-term nonprogressors and progressors to restrict human immunodeficiency virus replication is not caused by loss of recognition of autologous viral gag sequences. J Virol 2003;77:6889-98.
127. Kelleher AD, Long C, Holmes EC, Allen RL, Wilson J, Conlon C, et al. Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. J Exp Med 2001;193:375-86.